Skip to main content

REVIEW article

Front. Immunol.
Sec. Immunological Tolerance and Regulation
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1511671

T-regulatory cells for the treatment of autoimmune diseases

Provisionally accepted
Marina Fisher Marina Fisher *Sergey Sennikov Sergey Sennikov *
  • Research Institute of Fundamental and Clinical Immunology (RIFCI), Novosibirsk, Russia

The final, formatted version of the article will be published soon.

    Autoimmune diseases result from imbalances in the immune system and disturbances in the mechanisms of immune tolerance. T-regulatory cells (Treg) are key factors in the formation of immune tolerance. Tregs modulate immune responses and repair processes, controlling the innate and adaptive immune system. The use of Tregs in the treatment of autoimmune diseases began with the manipulation of endogenous Tregs using immunomodulatory drugs. Then, a method of adoptive transfer of Tregs grown in vitro was developed. Adoptive transfer of Tregs includes polyclonal Tregs with non-specific effects and antigen-specific Tregs in the form of CAR-Treg and TCR-Treg.This review discusses non-specific and antigen-specific approaches to the use of Tregs, their advantages, disadvantages, gaps in development, and future prospects.

    Keywords: T-regulatory cells, Autoimmune Diseases, immunological tolerance, polyclonal Tregs, CAR-Treg, TCR-Treg, antigen-specific therapy

    Received: 15 Oct 2024; Accepted: 17 Jan 2025.

    Copyright: © 2025 Fisher and Sennikov. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Marina Fisher, Research Institute of Fundamental and Clinical Immunology (RIFCI), Novosibirsk, Russia
    Sergey Sennikov, Research Institute of Fundamental and Clinical Immunology (RIFCI), Novosibirsk, Russia

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.